ECARX Announces Completion of the Final Tranche of US$100 million Convertible Notes

ECARX Announces Completion of the Final Tranche of US$100 million Convertible Notes

LONDON, Feb. 10, 2026 /PRNewswire/ -- ECARX Holdings Inc. (Nasdaq: ECX) ("ECARX" or the "Company"), a global mobility tech provider, today announced that the aggregate US$100 million in convertible notes (the "2025 Notes") contemplated by the...

Nexdata Announces Completion and Full Operation of Its World-Class Embodied AI Data Collection Factory

Nexdata Announces Completion and Full Operation of Its World-Class Embodied AI Data Collection Factory

SINGAPORE, Jan. 27, 2026 /PRNewswire/ -- As embodied AI rapidly evolves from foundation models and software-based agents toward real-world intelligent robots, the industry is facing a critical bottleneck: the large-scale availability of...

Sisram Medical Reports Completion of NIFDC Testing for DAXXIFY in China

Sisram Medical Reports Completion of NIFDC Testing for DAXXIFY in China

Marking a Key Milestone Toward Market Launch and Strengthening Sisram's Premium Aesthetics Portfolio HONG KONG, Jan. 5, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred...

Admission To Trading on The London Stock Exchange and Completion of Secondary Listing

Admission To Trading on The London Stock Exchange and Completion of Secondary Listing

PARIS, NEW YORK, and LONDON, Dec. 10, 2025 /PRNewswire/ -- The Generation Essentials Group ("TGE" or the "Company", NYSE and LSE: TGE) refers to its announcement published on December 5, 2025 relating to the approval by the UK Financial Conduct...

Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China

Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China

SAN FRANCISCO and SUZHOU, China, June 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of...

menu
menu